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Stromal Cell Identity Influences the In Vivo Functionality
of Engineered Capillary Networks Formed by Co-delivery
of Endothelial Cells and Stromal Cells
Stephanie J. Grainger, PhD, Bita Carrion, PhD, Jacob Ceccarelli, MS, and Andrew J. Putnam, PhD
A major translational challenge in the fields of therapeutic angiogenesis and tissue engineering is the ability to
form functional networks of blood vessels. Cell-based strategies to promote neovascularization have been
widely explored, and have led to the consensus that co-delivery of endothelial cells (ECs) (or their progenitors)
with some sort of a supporting stromal cell type is the most effective approach. However, the choice of stromal
cells has varied widely across studies, and their impact on the functional qualities of the capillaries produced has
not been examined. In this study, we injected human umbilical vein ECs alone or with normal human lung
fibroblasts (NHLFs), human bone marrow-derived mesenchymal stem cells (BMSCs), or human adipose-derived
stem cells (AdSCs) in a fibrin matrix into subcutaneous pockets in SCID mice. All conditions yielded new
human-derived vessels that inosculated with mouse vasculature and perfused the implant, but there were
significant functional differences in the capillary networks, depending heavily on the identity of the co-delivered
stromal cells. EC-alone and EC-NHLF implants yielded immature capillary beds characterized by high levels of
erythrocyte pooling in the surrounding matrix. EC-BMSC and EC-AdSC implants produced more mature
capillaries characterized by less extravascular leakage and the expression of mature pericyte markers. Injection of
a fluorescent tracer into the circulation also showed that EC-BMSC and EC-AdSC implants formed vasculature
with more tightly regulated permeability. These results suggest that the identity of the stromal cells is key to
controlling the functional properties of engineered capillary networks.
Introduction
Therapeutic angiogenesis, the process of promotingneovascularization and tissue repair via the delivery of
pro-angiogenic molecules, has been explored as a possible
means to treat ischemic diseases.1 However, clinical trials
relying on bolus injection of individual factors have been
disappointing,2 perhaps due to the limited half-life of most
protein growth factors, the lack of temporal and spatial
control over growth factor release, and the inability of single
factors to properly regulate neovascularization.3,4 Newer
strategies involving sustained delivery of pro-angiogenic
factors or genes from biodegradable scaffolds to overcome
protein stability issues,5–8 as well as delivery of multiple
pro-angiogenic factors in a time-dependent fashion to mimic
the process of natural vessel development,4,9 have been
shown to induce formation of vascular networks. However,
even combinations of multiple factors may not fully reca-
pitulate the complex milieu of pro-angiogenic signals pre-
sented to cells in vivo.
Cell-based therapies have also been explored to more
completely mimic the cascade of signals needed to promote
the formation of stable neovasculature. These approaches
involve delivering appropriate cell types that can directly
differentiate into capillary structures or provide a physio-
logic mixture of pro-angiogenic cues to accelerate the re-
cruitment of host vessels. A variety of cell types have been
shown to form new capillary networks and/or induce col-
lateral blood vessel development after implantation
in vivo.10–13 In addition, cells have been implanted using a
wide range of scaffold materials and extracellular matrix
proteins to improve cell retention and engraftment.14,15
However, most studies have relied on the presence of red
blood cells in lumen-like structures revealed via histology as
the sole metric of vessel functionality.
A particular challenge for the tissue-engineering commu-
nity is to induce vascularization of ischemic tissues with
blood vessels that are functionally normal. When vasculari-
zation is induced too rapidly, as in tumor angiogenesis, en-
dothelial cells (ECs) do not properly align.16,17 Blood vessel
growth induced by tumor expansion often results in abnor-
mal branching and growth patterns, defective endothelial
wall structures, and an abnormal pericyte coat.18 These ab-
normal characteristics relative to healthy vasculature can
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lead to capillaries that are leaky and unable to properly
control permeability, contributing to edema in the tissue.19,20
In the case of engineered capillary networks, our laboratory
and many others have had some previous success in induc-
ing capillary growth in both 3D in vitro cultures,21 and in vivo
subcutaneous implants.22 The results from such studies have
led to the consensus that co-delivery of ECs and a secondary
mesenchymal cell type produces the necessary cues to induce
tubular sprouting of ECs, and stromal cell differentiation
toward a pericytic phenotype.23
Despite the consensus of this paradigm, there is virtually
no consensus with respect to the choice of cells to co-deliver
with ECs. A variety of stromal cell types of mesenchymal
origins have been explored, including mesenchymal stem
cells from bone marrow21,24,25 or adipose tissue,26,27 fibro-
blasts from human lung,28,29 and mouse embryos,30 as well
as smooth muscle cells.31 For a subset of these cell types, our
previous studies using in vitro models have shown that
stromal cell identity underlies differences in the mechanisms
by which capillaries are formed,24,26 and in the functional
properties of the resulting capillaries.32 The goal of this study
was to determine if the identity of the stromal cells co-
delivered with ECs had any similar consequences on the
functional properties of engineered capillary networks in vivo
(Fig. 1). Our results suggest that the identity of the stromal
cells significantly influences the in vivo functionality of en-
gineered capillary networks.
Materials and Methods
Cell culture
Human umbilical vein endothelial cells (HUVECs, here-
after referred to as ECs) were harvested from fresh umbilical
cords following a previously established protocol,21 and
were grown in a fully supplemented endothelial growth
medium (EGM-2; Lonza) at 37C and 5% CO2. Normal hu-
man lung fibroblasts (NHLFs; Lonza) were cultured in
Media 199 (Invitrogen) supplemented with 10% fetal bovine
serum (FBS), 1% penicillin/streptomycin (Mediatech), and
0.5% gentamicin (Invitrogen). Bone marrow-derived mesen-
chymal stem cells (BMSCs; Lonza, passage 2) were tested by
the manufacturer for purity by flow cytometry and for their
ability to differentiate into osteogenic, chondrogenic, and
adipogenic lineages. Cells are positive for the cell surface
markers CD105, CD166, CD29 (integrin b1), and CD44, and
negative for CD14, CD34, and CD45. Both BMSCs and adi-
pose-derived stem cells (AdSCs; Invitrogen) were cultured in
the Dulbecco’s modified Eagle’s Medium (DMEM; Sigma-
Aldrich) supplemented with 10% FBS, 1% penicillin/strep-
tomycin (Mediatech), and 0.5% gentamicin (Invitrogen).
NHLFs, BMSCs, and AdSCs were all used before passage 10.
ECs were used at passage 3. Cells were cultured in mono-
layers until reaching 80% confluency and serially passaged
using 0.05% trypsin–EDTA treatment.
Tissue-construct implantation
Animal procedures were performed in accordance with
the NIH guidelines for laboratory animal usage following a
protocol approved by the University of Michigan’s Com-
mittee on Use and Care of Animals. Male 7-week-old C.B.-
17/SCID mice (Taconic Labs) were used for all experiments.
An anesthetic/analgesic drug cocktail of ketamine (95mg/
kg; Fort Dodge Animal Health), xylazine (9.5mg/kg; Lloyd
Laboratories), and buprenorphine (0.059mg/kg; Bedford
Laboratories) was delivered to each mouse via intraperito-
neal injection. The dorsal flank of each mouse was then
shaved, sterilized with betadine (Thermo Fisher Scientific),
and wiped down with an alcohol pad before implant
injection.
A 2.5mg/mL bovine fibrinogen solution (Sigma-Aldrich)
was made in serum-free EGM-2 and filtered through a 0.22-
mm syringe filter. Cell mixtures in a 1:1 ratio of EC:stromal
cells (NHLFs, BMSCs, or AdSCs) were spun down and re-
suspended in the previously prepared fibrinogen solution at
a final concentration of 10 million cells/mL, totaling 3 mil-
lion cells per injection sample (300mL total volume). Im-
mediately before injection, 5% FBS and 6 mL of thrombin
solution (50U/mL; Sigma-Aldrich) were added to 300 mL of
fibrinogen–cell solution. For control samples, 3 million ECs
without any stromal cell type were used. Acellular controls
containing fibrinogen, FBS, and thrombin were also in-
cluded. Solutions were immediately injected subcutaneously
on the dorsal flank of the mouse, with two implants per
animal. Animals were kept stationary for 5min to allow for
implant polymerization, and were then placed in fresh cages
for recovery. Five replicates of each sample type were com-
pleted (EC-NHLF, EC-BMSC, EC-AdSCs, EC only, and
acellular). Surgeons were not blinded to the experimental
conditions. Implants were retrieved after 7 or 14 days, con-
sistent with the time points used in several other neovascu-
larization studies.9,33–36
Noninvasive laser Doppler perfusion imaging
At days 3, 7, 10, and 14, mice were anesthetized using the
cocktail described above, and then subjected to laser Doppler
FIG. 1. Method to engineer vascular networks in vivo. In
this study, EC alone or in combination with one of three
different types of stromal cells (NHLFs, AdSCs, or BMSCs)
were injected subcutaneously within a fibrin matrix on the
dorsal surface of SCID mice. Injected cells form a provisional
vascular network that inosculates with the systemic circula-
tion. AdSC, adipose-derived stem cell; BMSC, bone marrow-
derived mesenchymal stem cell; EC, endothelial cell; NHLF,
normal human lung fibroblast. Color images available online
at www.liebertpub.com/tea
1210 GRAINGER ET AL.
perfusion imaging (LDPI; Perimed AB). Each mouse was
imaged in triplicate. Results are reported as folds increased
in relative perfusion units over untreated controls.
Tracer injection and implant removal
Mature capillaries function as selectively permeable
membranes and are known to be impermeable to dextrans
over a molecular weight of 65 kDa.37 Therefore, a 70-kDa
Texas Red-conjugated dextran (lex/em of 595/615 nm; In-
vitrogen) was chosen as a functionally defining tracer. This
dextran molecule, containing free lysines, is fixable in 4%
PFA. At each retrieval time point, final LDPI was com-
pleted, and each mouse was placed in a restraint device,
and 200 mL of a 5% dextran solution in PBS was then in-
jected via the tail vein. After injection, mice were placed
into fresh cages, and the tracer was allowed to circulate
systemically for 10min. Animals were then euthanized,
and implants, including the surrounding skin and muscle
layers, were surgically excised.
Whole-mount live imaging
Explants were placed onto Petri dishes after removal and
immediately imaged using an Olympus IX81 spinning-disk
confocal microscope (Olympus) with both a Hamamatsu
camera for visualization of the fluorescent dextran tracer
(Supplementary Fig. S1; Supplementary Data are available
online at www.liebertpub.com/tea), and a DP2-Twain
(Olympus) camera for color bright-field images. Macroscopic
images were taken using a Kodak EasyShare Z1015 IS
camera (Kodak).
Histology and immunohistochemistry
For histology and immunohistochemical staining, ex-
plants were fixed in 4% PFA for 1 h, 0.4% PFA overnight,
and then transferred to a PBS, pH 7.4, solution, all at 4C.
All samples were forwarded to AML Laboratories for
sectioning. Samples were embedded in paraffin by AML,
and then sectioned in 5-mm sections and stained with
hematoxylin and eosin (H&E) according to standard pro-
tocols. All sample identities were masked to the tissue
processor. hCD31, alpha-smooth muscle actin (a-SMA),
and calponin were immunohistochemically stained in our
laboratory on unstained serial sections provided by AML.
Paraffin sections were rehydrated according to a standard
protocol22 and then steamed in a vegetable steamer for
25min in an antigen retrieval solution (Dako). Slides were
equilibrated in TBS-T, and then a DakoEnVision System-
HRP (DAB) kit (Dako) was used for all subsequent staining.
The primary antibody (human anti-mouse CD31; Dako,
human anti-mouse a-SMA; Abcam, or human anti-mouse
calponin; Abcam) was diluted 1:50 in TBS-T and incubated
at 4C overnight. Slides were then treated with an HRP-
conjugated anti-mouse secondary antibody provided in the
kit, followed by H&E counterstaining. Negative controls
using the secondary antibody alone were generated in
parallel to ensure that nonspecific staining did not occur.
Immunofluorescent staining
For fluorescent staining, explanted tissue samples were
initially incubated in 30% sucrose for 48 h at 4C. They were
then transferred to a solution containing one part optimal
cutting temperature (OCT) embedding compound (Andwin
Scientific), and two parts 30% sucrose for another 24 h. Each
sample was then finally embedded in 100% OCT within a
disposable plastic mold (Fisher Scientific), and flash-frozen
on the surface of liquid nitrogen. These frozen samples were
then forwarded to AML Laboratories for cryosectioning in
5-mm sections. Frozen sections returned to our laboratory
were prewarmed for 20min at 25C. Slides were submerged
in PBS, pH 7.4, for three separate 5min washes, and then
blocked using 5% goat serum in PBS to eliminate nonspecific
protein binding. The primary antibody (anti-rabbit human
CD31; Santa Cruz Biotechnologies) was diluted 1:50 in 5%
goat serum and incubated at 4C overnight. After incubation,
the unbound antibody was removed with three washes of
5min each with PBS. The secondary antibody (Alexa Fluor-
488 goat anti-rabbit; Invitrogen) at a 1:100 concentration was
incubated for 30min at room temperature. The unbound
antibody was removed with three washes of 5min each with
PBS. Slides were then covered with VectaShield (Vector
Labs) and a #1 glass coverslip.
Image analysis program for quantification
A customized MATLAB algorithm, described previous-
ly,32 was modified to quantify the relative amounts of
fluorescent dextran within vessel lumens and the interstitial
spaces of the tissue implant. Briefly, images of the green
channel (Alexa Fluor 488-hCD31) were first used to deter-
mine the location of the implanted human ECs. Using
hCD31-positive staining as a guide, the capillaries within
the implants in each tissue section were then identified and
traced manually by the researchers; H&E-stained serial
sections were used to confirm the location of the capillaries
based on the presence of host erythrocytes within well-
defined lumens. The red channel (Texas Red–dextran) was
then overlayed, and the percentages of its localization, ei-
ther within the capillaries or external to the capillaries, were
determined using the following algorithm.
Ri¼ total red(inside and outside)of vessel i
ri¼ total red inside of vessel i
Therefore, for a single vessel, the red outside is r¢i ¼ Ri ri
(where r’ is the total red outside of the lumens). The total red
outside of all the vessels in the image is represented as fol-
lows:
+
n
i¼ 1
Ri ri
This quantity was then normalized to the overall red (inside
and out) within each image to yield a metric representing the
quantity of fluorescent signal outside of the lumens.
r¢¼ +
n
i¼ 1Ri ri
+ni¼ 1Ri
Note that since s R a n (the numbers of vessels), normalizing
the extralumenal signal by the overall fluorescent intensity of
the image accounts for variations in size, shape, and num-
bers of vessels.
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Quantification of average number of vessels
per field of view
Using hCD31-stained slides, the number of blood vessels
derived from implanted cells was quantified manually.
Blood vessels were identified if they exhibited a rim of
positive hCD31 stain and a hollow lumen containing
erythrocytes. Three sections, with five randomly taken im-
ages per section at 20 · , were used to achieve statistical
significance, and evaluators were masked to the experi-
mental conditions. All values were normalized to represent
a 1-mm2 area.
Statistical analysis
All statistical analyses were performed using GraphPad
Prism (GraphPad Software). Data were reported as
mean – standard deviation. Two-way analysis of variance
was performed with a Newman–Keuls multiple compari-
son post-test. Statistical significance was assumed when
p < 0.05.
Results
Co-injection of ECs with supporting stromal
cells restored perfusion
In this study, ECs alone or in combination with one of
three different types of stromal cells (NHLFs, AdSCs, or
BMSCs) were injected subcutaneously within a fibrin matrix
on the dorsal surface of SCID mice as depicted schematically
in Figure 1. LDPI was used to noninvasively quantify blood
perfusion after subcutaneous injection of one of five treat-
ment groups. LDPI was first performed on all mice before
implantation to provide a baseline control value of dorsal
vascular perfusion. It was then performed again on days 3, 7,
10, and 14 post-implantation. As shown in Figure 2, relative
perfusion values increased over the course of the experiment
for all treatment groups; however, key differences were seen
among different conditions. Co-delivery of ECs with AdSCs,
BMSCs, or NHLFs within a fibrin matrix successfully re-
stored blood flow to preinjection levels within 7 days. The
restored level of perfusion was maintained at 14 days for
these multicellular implants. By comparison, delivery of ECs
alone partially restored blood flow by 7 days, but perfusion
dropped off in the subsequent 7 days. Acellular fibrin gels
failed to restore perfusion to preinjection levels within 14
days.
Live implant imaging qualitatively confirmed
perfusion of the neovasculature
Immediately after implant removal, whole-mount live
imaging was performed, revealing some qualitative, yet
striking, differences in the appearance of the explanted tis-
sues (Fig. 3). At day 7, all of the retrieved implants were red,
perhaps indicative of connecting to the host vasculature, al-
though the implant from the EC-NHLF condition was no-
tably the most red (Fig. 3A). The visible redness suggests
erythrocyte leakage into the implant. After 14 days (Fig. 3B),
the bright red color remained present in the EC-alone and
EC-NHLF conditions; by contrast, the red color diminished
in the EC-AdSC and EC-BMSC implants. Implants for these
latter two conditions were pale pink/yellow color in mac-
roscopic appearance by day 14, yet retained easily identifi-
able blood vessels that were bright red in color. At this later
time point, the fibrin also appeared somewhat more com-
pacted and perhaps more degraded in the EC-alone and EC-
NHLF conditions.
Stromal cells of different origins produced vessels
with distinct morphologies
Images of the H&E-stained day-7 and day-14 explants
revealed additional qualitative differences in the morpho-
logies of the vessels formed in the various experimental
groups (Fig. 4). Stained sections from the day-7 EC-only
implants contained many large vessel-like structures, but
these structures lacked consistent, circumscribed geometry,
and the implants contained obvious extravascular erythro-
cytes (Fig. 4A). Significant vessel regression and matrix
degradation were apparent by day 14 (Fig. 4B). The cells
that remained in the fibrin by day 14 were mainly spindle-
shaped free ECs, and there was little evidence of organi-
zation into capillary structures. EC-NHLF implants also
FIG. 2. Subcutaneous co-injection of EC and supporting stromal cells within fibrin matrices restore perfusion better than
delivery of EC alone. Laser Doppler perfusion imaging was used to noninvasively quantify blood perfusion after subcuta-
neous injection of one of five treatment groups (all within fibrin gels): ECs, EC-AdSCs, EC-BMSCs, EC-NHLFs, or fibrin
alone. a, b, c, and d denote statistically significant differences ( p < 0.05) within each experimental group (i.e., a is different
than b, etc.). e and f indicate statistically significant differences ( p < 0.05) across the different experimental groups (i.e., e
is different than f across groups, but all the e’s are statistically the same). Color images available online at www
.liebertpub.com/tea
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contained many immature, interconnected blood vessels at
day 7 (Fig. 4A), but it was difficult to discern clear vessel
boundaries due to the somewhat chaotic and irregular
shapes of the vessel-like structures and large amounts of
matrix reorganization. After 14 days, there appeared to be a
qualitative decrease in the amount of free erythrocytes in
the explanted EC-NHLF tissues, but some still remained. By
contrast, implants containing the multipotent stromal cells
(AdSCs or BMSCs) yielded starkly different results. These
samples contained many small capillaries with very well-
defined lumens, circumscribed borders, and very few free
erythrocytes. These capillaries were distributed throughout
the entire implant to produce a vascularized, homogeneous
implant containing both large and small blood vessels
throughout to effectively supply the tissue with oxygenated
blood.
Immunohistochemical staining for human CD31 validated
the observations from the H&E-stained sections, and con-
firmed the human origins of the neovasculature (Fig. 5). In
the implants containing ECs only, there was a diffuse brown
stain indicating an abundance of human ECs and some
lumen-like structures, especially at day 7 (Fig. 5A). The EC-
NHLF implants showed many elongated vessel-like struc-
tures. By contrast, the EC-BMSC and EC-AdSC implants
contained many smaller, tightly sealed capillaries, consistent
with the observations from H&E staining. Quantification of
FIG. 3. Whole-mount live
imaging shows perfusion of
implant neovessels. Explants of
each treatment group imaged as
live whole-mounts at (A) day 7 and
(B) day 14. Insets are macroscopic
photographs. Color images
available online at
www.liebertpub.com/tea
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vascular density from these types of images supported these
qualitative observations. Specifically, EC-only implants con-
tained 46– 3 vessels per mm2 at 7 days, but this value
dropped to 9 – 2 vessels per mm2 by day 14. EC-NHLF im-
plants contained 47– 6 vessels per mm2 at day 7, which was
reduced to 31 – 2 vessels per mm2 by day 14. Relative to these
two conditions, the EC-AdSC and EC-BMSC implants pro-
duced fewer numbers of blood vessels. EC-AdSC implants
contained 29– 7 and 19 – 4 vessels per mm2 at days 7 and 14,
respectively. EC-BMSC implants formed 20 – 4 and 13– 3
vessels per mm2 at days 7 and 14, respectively. Acellular
fibrin implants showed little evidence of vascularization or
host network invasion (see Supplementary Fig. S1). By 14
days post-implantation, the fibrin implants had been re-
sorbed by the host, and normal host dorsal vasculature was
observed at the implantation site.
FIG. 4. Histological staining
illustrates varying blood vessel
morphologies in implants across
treatment groups. Histologically
stained sections of implants
retrieved at (A) day 7 or (B) day 14
post-injection. Insets are higher-
magnification (60 · ) micrographs to
more clearly show vessel
morphologies. Color images
available online at
www.liebertpub.com/tea
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Stromal cells with multilineage potential express
markers of mature smooth muscle
One possible explanation for the observed differences in
vessel morphology is that the multipotent stromal cells may
possess the ability to differentiate into pericytes, or even
mature smooth muscle cells, while the fibroblasts cannot. To
assess this possibility in our experimental system, we stained
histological sections for two different markers—a-SMA and
calponin (Fig. 6). a-SMA has been widely used as a pericyte
marker,18 whereas calponin is a marker of mature smooth
muscle.38 IHC staining of human a-SMA revealed a broadly
positive result for all of the implants containing a co-delivered
stromal cell type, particularly at day 7 (Fig. 6A). By day 14,
this positive staining had somewhat decreased across all
multicellular implants. In the EC-BMSC and EC-AdSC im-
plants, positive a-SMA staining was circumferentially locali-
zed around the newly developed blood vessels, while the
FIG. 5. Human CD31 staining
confirms blood vessel origin.
hCD31 staining of implants at either
(A) day 7 or (B) day 14 post-
implantation. All samples have
been counterstained with H&E.
Insets are higher-magnification
(60 · ) micrographs to more clearly
show vessel morphologies. (C)
Quantification of images from (A)
and (B). In the graph, ‘‘a’’ denotes
statistical significance ( p< 0.05)
between time points within an
experimental group. Across
experimental groups, data marked
with different letters are statistically
different ( p < 0.05) (i.e., ‘‘b’’ is
different than ‘‘c’’), while those
marked with the same letters are
not (i.e., differences across all of the
‘‘b’s’’ are insignificant). H&E,
hematoxylin and eosin. Color
images available online at
www.liebertpub.com/tea
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EC-NHLF implants contained a more diffuse positive stain-
ing of cells throughout the matrix. By contrast, calponin
staining was only positive at day 14 in the implants con-
taining AdSCs or BMSCs (Fig. 7, particularly panel B). These
results suggest that while NHLFs, AdSCs, and BMSCs are all
capable of promoting the formation of vasculature and ex-
pressing a-SMA, only the multipotent AdSCs and BMSCs are
capable of differentiating into a mature smooth muscle
phenotype that is the hallmark of a larger and more mature
vasculature.
Stromal cell presence and identity alter the functional
permeability of the neovessels
The data presented thus far suggest that all 3 stromal cell
types—NHLFs, AdSCs, and BMSCs—are capable of pro-
moting the formation of vasculature in subcutaneous pockets
when co-delivered with ECs. The histological findings hint at
possible functional differences in the neovessels that form,
but nearly all of the observed differences have been quali-
tative, subjective, and frankly unsatisfying. Therefore, in the
final part of this study, we sought to determine how the
inclusion of the stromal cells and their various identities
quantitatively affects the functional properties of engineered
capillary networks.
Based on some recent in vitro findings, we hypothesized
that the resistance to permeability of the nascent vessels
would strongly depend on stromal cell identity.32 To quan-
tify the relative permeabilities of the vasculature formed
in vivo, a 70-kDa fluorescent dextran molecule was injected
via tail vein in the various experimental animals (systemic
injection of the functionally defining tracer can be seen at the
host–implant interface in Supplementary Fig. S2). Inclusion
of either AdSCs or BMSCs in the implants resulted in much
tighter control of permeability relative to the other conditions
(Fig. 8). In the EC-only and EC-NHLF groups, a significant
fraction of the fluorescent dextran was observed outside of
the vessel borders (defined by the green CD31 staining), and
freely diffused throughout the implant tissue (Fig. 8A). By
comparison, the EC-AdSC and EC-BMSC groups contained
very well-defined vessels in which the Texas Red–dextran
was circumscribed by human-CD31 + cells, with signifi-
cantly less red signal in the surroundings. Importantly, we
had also previously developed and validated an automated
MATLAB-based image-processing algorithm to quantify
vessel permeability.32 When we applied this algorithm to
quantify the relative fluorescence contained with lumens as
described in the Materials and Methods section, the re-
sulting data confirmed that co-delivery of ECs with AdSCs
or BMSCs yields vessels whose control of permeability is
superior (Fig. 8B).
Discussion
This study examined the quantity and functional quality
of engineered capillary networks formed via co-delivery of
ECs with one of three types of supporting stromal cells
(NHLFs, BMSCs, or AdSCs) in a fibrin-based subcutaneous
implant. Fibrin is a naturally occurring biopolymer that acts
as the provisional matrix during wound healing in the hu-
man body, and has been widely shown in the literature to
support neovascularization.22,33,35,39,40 The animal model
used here has also been widely exploited in the literature to
approximate wound healing and test the ability of trans-
planted human cells to form vasculature,19,22,29,33–35 in part
because the human cells injected into SCID mice are not re-
jected.
We focused our efforts on NHLFs, BMSCs, and AdSCs as
the stromal cell types in large part because of our own prior
in vitro work,24,26,32 which has suggested some differences in
the mechanisms by which these cells promote vasculariza-
tion. However, the use of these three types of stromal cells
has been gaining traction in the tissue-engineering literature
in recent years. In the case of fibroblasts, their co-delivery
with stem cell-derived cardiomyocytes and ECs has been
explored in the context of vascularized cardiac patches.41 A
high density of cotransplanted NHLFs, in particular, in a
prevascularized tissue construct has been shown to acceler-
ate the rate of inosculation between host vessels and the
implanted vessels.29 Likewise, AdSCs co-delivered with ECs
in collagen-based implants have been shown to enhance
vascularization, and to help sustain pancreatic islets or adi-
pocytes.34 There are also a number of studies that have ex-
plored the utility of BMSCs co-delivered with ECs to build
functional vasculature.22,25
The results presented here show that all four of the ex-
perimental groups (EC-alone, EC-NHLFs, EC-AdSCs, and
EC-BMSCs) yielded new human-derived vessels that in-
osculated with mouse vasculature and perfused the implant
with blood. However, functional differences in the capillary
networks were also revealed, depending on the identity of
the co-delivered stromal cells. Importantly, the observed
differences in vessel function were not apparent in data
generated by manually counting numbers of vessels in H&E-
or hCD31-stained histological sections, the most common
endpoint utilized to assess functional connections between
implanted capillary beds and the host vasculature.
LDPI was also used to assess blood flow, and provided an
indirect indication of inosculation between the host vessels
and the newly developed vasculature within the implant.
This method has been widely employed in the tissue-engi-
neering literature to assess the success of revascularization
therapies.42,43 The main advantages of this technology are its
noninvasive and real-time measuring capabilities. In our
study, mice were anesthetized for a short period and
FIG. 5. (Continued).
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experiments performed longitudinally across multiple time
points with the same mouse. However, LDPI results may be
somewhat misleading, as the data in Figure 2 suggest. Spe-
cifically, we found that co-delivery of ECs with AdSCs,
BMSCs, or NHLFs within a fibrin matrix successfully re-
stored blood flow to preinjection levels, with no significant
differences between them. Delivery of ECs alone partially
restored blood flow by 7 days, but perfusion dropped off in
the ensuing 7-day period. From these data alone, one might
conclude that AdSCs, BMSCs, and NHLFs are all equal with
respect to their ability to promote functional vessels that can
perfuse an implant. However, erythrocyte pooling and ede-
ma into the implants could not be quantified via LDPI.
Macroscopic images (Fig. 3) suggested some differences
across the different experimental groups. EC-NHLF implants
were visibly red to the naked eye, especially at the day-7
timepoint. EC-BMSC and EC-AdSC implants were signifi-
cantly lighter in color by comparison. Implants containing
only ECs were somewhere in between in gross appearance.
H&E staining of the retrieved implants (Fig. 4) revealed
FIG. 6. a-SMA staining identifies
stromal cells within the implant.
Human a-SMA staining (brown)
and counterstaining with H&E at
(A) 7 days and (B) 14 days post-
implantation. Arrows point to
representative positive a-SMA
around vessels, but prevalent
positive staining is present in all
implants that contain stromal cells
at both time points. a-SMA, alpha-
smooth muscle actin. Color images
available online at
www.liebertpub.com/tea
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many free erythrocytes within the EC-only and EC-NHLF
implants. The presence of multipotent stromal cells, from
either bone marrow or adipose, yielded smaller, more well-
defined blood vessels throughout the implants. These vessels
appeared to be tightly lined with ECs, as identified by the
hCD31 staining (Fig. 5A, B). However, manual quantification
of perfused lumen-containing structures on these hCD31-
stained sections (Fig. 5C) seemed to suggest that EC-NHLF
co-delivery was superior to EC-BMSC or EC-AdSC co-
delivery in terms of numbers of vessels. Implants containing
ECs alone also appeared to yield greater numbers of vessels
initially, but these vessels were unstable in the absence of a
co-delivered stromal cell. In fact, it was only when we as-
sessed the permeability of the engineered vessel networks by
systemically injecting a fluorescent tracer into the host cir-
culation that the functional superiority of co-delivering ECs
with the multipotent stromal cells emerged. As shown in
Figure 8, a significant fraction of the Texas Red–dextran
FIG. 7. Calponin staining
identifies mature smooth muscle
cells within the implant. Calponin
staining (brown) and
counterstaining with H&E at (A) 7
days and (B) 14 days post-
implantation. Arrows point to
representative positive calponin
around vessels, which is only
observed in EC-BMSC and EC-
AdSC conditions at day 14. Color
images available online at
www.liebertpub.com/tea
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leaked outside of the vessel borders in the EC-only and EC-
NHLF groups, especially at the day-7 timepoint. By com-
parison, the fluorescent dextran was better retained with the
vessels in the EC-AdSC and EC-BMSC groups.
There are numerous possible explanations for the superior
functional properties of the vessels created in the EC-AdSC
and EC-BMSC groups. One possibility is that the multipotent
AdSCs and BMSCs are capable of differentiating into peri-
cytes, and perhaps even functional smooth muscle, while the
NHLFs are not. However, assessing this possibility is diffi-
cult due to the limited availability of bona fide pericyte
markers. Smooth muscle a-actin is commonly used as a
pericyte marker,44,45 but it is also a marker of myofibro-
blasts.46 In our results, the EC-only condition is negative for
a-SMA, but all of the other conditions show some degree of
positive staining (Fig. 6). The EC-NHLF implants show
several small, stippled areas of positive staining. By contrast,
only the EC-AdSC and EC-BMSC implants show positive
FIG. 8. Co-injection of ECs with AdSCs or BMSCs yields neovasculature with superior functional properties. (A) SCID mice
were subjected to tail vein injections of 70-kDa Texas Red–dextran (red) tracer to visualize inosculation and characterize
vessel leakiness. Tissues were counterstained with anti-human CD31 antibodies (green) to verify the human origins of the
vessels. (B) Quantitative results of the relative amounts of red tracer both inside and outside of capillary vessels achieved
using a custom MATLAB image-processing algorithm. In the graph, ‘‘a’’ denotes statistical significance ( p < 0.05) between
time points within an experimental group. Across experimental groups, data marked with either ‘‘b’’ or ‘‘c’’ are statistically
different ( p < 0.05) from other data marked with the same letter (i.e., all of the ‘‘b’s’’ are different from each other). Color
images available online at www.liebertpub.com/tea
ENGINEERING FUNCTIONAL CAPILLARY NETWORKS IN VIVO 1219
calponin staining, an indication of possible smooth muscle
differentiation, and only after 14 days (Fig. 7), implying
evolvement of a smooth muscle-like phenotype of implanted
stromal cells. Together, these two pieces of data suggest that
the AdSCs and BMSCs may be able to differentiate into
functional pericytes, and eventually smooth muscle cells,
and thus are better able to stabilize the new vessel networks
and modulate their permeability. By contrast, the terminally
differentiated NHLFs (and perhaps fibroblasts, more gener-
ally) act more as myofibroblasts in a wound-healing envi-
ronment, rapidly promoting vessel formation to heal the
wound. Prior results from an in vitro comparison of these
different stromal cell types show that NHLFs promote cap-
illary morphogenesis at a faster rate,32 consistent with this
possible explanation.
A second possibility is that the various stromal cell types
survive to differing degrees after implantation. This could
lead to different numbers of stromal cells, which may in
turn affect the number and quality of the resulting vessels
that form. A third possibility is that the various stromal cell
types secrete distinct pro- and antiangiogenic cytokines that
regulate vessel maturation, and/or differentially contribute
to the production of new ECM proteins required for vessel
formation and stability.47 A final possibility relates to the
influence of stromal cell identity on the proteolytic re-
modeling of the ECM during the neovascularization pro-
cess.24,48 Our published data suggest that capillary
formation induced by fibroblasts is very fast (perhaps tu-
mor-like), resulting from a plasmin-mediated proteolysis
that rapidly degrades the matrix and disrupts its mechani-
cal properties in a global fashion. By contrast, BMSCs and
AdSCs induce a much more focal, strategic matrix re-
modeling that is MT1-MMP dependent and results in
capillaries that form more slowly, but also in a more stable
manner. These kinetic differences in capillary morphogen-
esis controlled by matrix breakdown ultimately determine
the functional permeability and stability of the resulting
vasculature. An essential step in our ongoing efforts to
evaluate this hypothesis was to show that stromal cell
identity does indeed regulate vessel quality in vivo, as we
have done here. However, we do not yet have any defini-
tive experimental data that allow us to dismiss any of these
or other potential mechanisms.
In conclusion, the results of this study suggest that the
identity of the stromal cells co-delivered with ECs is key to
controlling the functional properties of vasculature en-
gineered via cell delivery, and argue that multipotent stro-
mal cells with the ability to differentiate in situ are superior
to terminally differentiated fibroblasts. Importantly, this
study also underscores the need for more quantifiable met-
rics of functionality, rather than relying solely on the manual
counting of the numbers of vessels in histological sections.
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